Akorn gets FDA nod for generic Flonase
Akorn has received the Food and Drug Administration's clearance for azelastine hydrochloride nasal spray, 0.15%.
The product is the generic of GSK's Flonase.
It is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 6 years of age and older and perennial allergic rhinitis in patients 6 years of age and older.
Azelastine hydrochloride nasal spray, 0.15% had a market value of roughly $18 million for the 12 months ended June 2019, according to IQVIA.
The product is the generic of GSK's Flonase.
It is indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 6 years of age and older and perennial allergic rhinitis in patients 6 years of age and older.
Azelastine hydrochloride nasal spray, 0.15% had a market value of roughly $18 million for the 12 months ended June 2019, according to IQVIA.